MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Phenylbutyric Acid
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phenylbutyric acid.
Abiraterone
The serum concentration of Fesoterodine can be increased when it is combined with Abiraterone.
abobotulinumtoxinA
Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Acebutolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.
Acetyl Sulfisoxazole
The metabolism of Fesoterodine can be decreased when combined with Acetyl sulfisoxazole.
Aclidinium
Fesoterodine may increase the anticholinergic activities of Aclidinium.
Ajmaline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ajmaline.
Alfentanil
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Alphaprodine.
Ambenonium
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ambenonium.
Amiodarone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.
Amitriptyline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.
Amlodipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.
Amodiaquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amodiaquine.
Amphetamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amphetamine.
Antipyrine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.
Apalutamide
The serum concentration of Fesoterodine can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Fesoterodine can be increased when it is combined with Aprepitant.
Aripiprazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.
Artemether
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Artemether.
Asenapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.
Atazanavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atazanavir.
Atomoxetine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.
Atorvastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.
Atracurium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Fesoterodine.
Azelastine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.
Benactyzine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.
Benzthiazide
The serum concentration of Benzthiazide can be increased when it is combined with Fesoterodine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Fesoterodine.
Betaxolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.
Bicalutamide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bicalutamide.
Biperiden
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.
Black Cohosh Extract
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimicifuga racemosa.
Boceprevir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.
Bortezomib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.
Bosentan
The serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.
Botulinum Toxin Type A
Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Brompheniramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.
Buprenorphine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.
Bupropion
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bupropion.
Butorphanol
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Butylscopolamine.
Carbamazepine
The metabolism of Fesoterodine can be increased when combined with Carbamazepine.
Carbinoxamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.
Carteolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.
Celecoxib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.
Ceritinib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ceritinib.
Cerivastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cerivastatin.
Chloroquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.
Chlorpheniramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.
CHLORPHENIRAMINE POLISTIREX
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Chlorphenoxamine.
Chlorpromazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.
Cholecalciferol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cholecalciferol.
Cimetidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.
Cinacalcet
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.
Cisapride
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cisapride.
Citalopram
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.
Clarithromycin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clarithromycin.
Clemastine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clemastine.
Clobazam
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clobazam.
Clofezone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.
Clomipramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.
Clotrimazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clotrimazole.
Clozapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.
Cobicistat
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cobicistat.
Cocaine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cocaine.
Codeine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.
Codeine Anhydrous
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.
CODEINE POLISTIREX
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Fesoterodine.
Crizotinib
The metabolism of Fesoterodine can be decreased when combined with Crizotinib.
Curcumin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Curcumin.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Fesoterodine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fesoterodine.
Cyclosporine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.
Cyproterone Acetate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyproterone acetate.
Dabrafenib
The serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.
Darifenacin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.
Darunavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darunavir.
Dasatinib
The serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.
Demecarium
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Demecarium.
Desipramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.
Desloratadine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Fesoterodine.
Dexfenfluramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.
Dexmedetomidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.
Dexmethylphenidate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmethylphenidate.
Dextroamphetamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextroamphetamine.
Dextromethorphan
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextromethorphan.
Dextromoramide
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dezocine.
Diacetylrhein
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diacerein.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.
Dihydroergotamine
The metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.
Diltiazem
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diltiazem.
Dimethyl Sulfoxide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide.
Diphenhydramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.
Dipivefrin
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Dipivefrin.
Distigmine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Distigmine.
Disulfiram
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Disulfiram.
Dolasetron
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dolasetron.
Donepezil
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Donepezil.
Dothiepin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dosulepin.
Doxepin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.
Doxorubicin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.
Doxorubicin Hydrochloride
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.
Doxycycline
The metabolism of Fesoterodine can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Fesoterodine can be decreased when combined with Doxycycline.
Dronedarone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.
Duloxetine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.
Echothiophate
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Edrophonium.
Efavirenz
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.
Eliglustat
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Eliglustat.
Eluxadoline
Fesoterodine may increase the constipating activities of Eluxadoline.
Enasidenib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Enasidenib.
Entacapone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Entacapone.
Enzalutamide
The serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.
Epinastine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Epinastine.
Erythromycin
The metabolism of Fesoterodine can be decreased when combined with Erythromycin.
Escitalopram
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.
Ethanol
Ethanol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Ethylmorphine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.
Etoricoxib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.
Felodipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.
Fenfluramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fenfluramine.
Fentanyl
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Fentanyl.
Fexofenadine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fexofenadine.
Flavoxate
The risk or severity of adverse effects can be increased when Flavoxate is combined with Fesoterodine.
Flavoxate Hydrochloride
The risk or severity of adverse effects can be increased when Flavoxate is combined with Fesoterodine.
Flecainide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Flecainide.
Fluconazole
The metabolism of Fesoterodine can be decreased when combined with Fluconazole.
Fluoxetine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.
Fluphenazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.
Fluvastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvastatin.
Fluvoxamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.
Fosamprenavir
The metabolism of Fesoterodine can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Fesoterodine can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Fesoterodine can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Fesoterodine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Fesoterodine can be increased when it is combined with Fusidic Acid.
Galantamine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fesoterodine.
Gefitinib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Gefitinib.
Ginkgo biloba extract
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.
Glycerol Phenylbutyrate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Glycerol Phenylbutyrate.
Glycopyrronium
Fesoterodine may increase the anticholinergic activities of Glycopyrronium.
Granisetron
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Granisetron.
Halofantrine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Halofantrine.
Haloperidol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
Heroin
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Heroin.
Histamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Histamine.
Homatropine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Fesoterodine.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.
Hydrocodone
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.
Hydromorphone
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.
Hydroxychloroquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine.
Hydroxyurea
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyurea.
Hydroxyzine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.
Hypoxis hemerocallidea root extract
The serum concentration of Fesoterodine can be decreased when it is combined with St. John's Wort.
Idarubicin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idarubicin.
Idelalisib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idelalisib.
Imatinib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.
Imipramine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.
incobotulinumtoxinA
Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Fesoterodine.
Indinavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Indinavir.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.
Ipratropium cation
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.
Irbesartan
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.
Isavuconazole
The serum concentration of Fesoterodine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Fesoterodine can be decreased when combined with Isavuconazonium.
Isoflurophate
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.
Isoniazid
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Isoniazid.
Isradipine
The metabolism of Fesoterodine can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.
Ivacaftor
The serum concentration of Fesoterodine can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ketoconazole.
Labetalol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.
Lansoprazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.
Lercanidipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.
Levalbuterol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Levosalbutamol.
Levomethadyl
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.
Lidocaine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.
Lomustine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lomustine.
Lopinavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.
Loratadine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Loratadine.
Lorcaserin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lorcaserin.
Lovastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lovastatin.
Luliconazole
The serum concentration of Fesoterodine can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Fesoterodine can be decreased when it is combined with Lumacaftor.
Lumefantrine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.
Malathion
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Malathion.
Manidipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Manidipine.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.
Mefloquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.
Methadone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadyl Acetate.
Methamphetamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methamphetamine.
Methantheline
The risk or severity of adverse effects can be increased when Methantheline is combined with Fesoterodine.
Methazolamide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methazolamide.
Methimazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.
Methixene
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Metixene.
Methotrimeprazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.
Methoxsalen
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methoxsalen.
Methscopolamine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.
Methylnaltrexone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone.
Methylphenidate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.
Metoclopramide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Fesoterodine.
Metoprolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.
Metylperon
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Melperone.
Mianserin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin.
Mibefradil
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mibefradil.
Miconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole.
Midodrine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midodrine.
Midostaurin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midostaurin.
Mifepristone
The serum concentration of Fesoterodine can be increased when it is combined with Mifepristone.
Minaprine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.
Mirabegron
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.
Mirtazapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.
Mitotane
The serum concentration of Fesoterodine can be decreased when it is combined with Mitotane.
Moclobemide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.
Morphine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.
Nabilone
Fesoterodine may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.
Naloxegol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Naloxegol.
Nefazodone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.
Nelfinavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.
Neostigmine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Neostigmine.
Netupitant
The serum concentration of Fesoterodine can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nevirapine.
Niacin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Niacin.
Niacinamide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicotinamide.
Nicardipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.
Nifedipine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.
Nilotinib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.
Normethadone
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Normethadone.
Nortriptyline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.
O-PHENANTHROLINE
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fesoterodine.
Octylonium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Otilonium.
Olanzapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.
Olaparib
The metabolism of Fesoterodine can be decreased when combined with Olaparib.
Omeprazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.
onabotulinumtoxinA
Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Ondansetron
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.
Osimertinib
The serum concentration of Fesoterodine can be increased when it is combined with Osimertinib.
Ospemifene
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ospemifene.
Oxamniquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxamniquine.
Oxitropium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxitropium.
Oxprenolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.
Oxybutynin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.
Oxymetholone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxymetholone.
Oxymorphone
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fesoterodine.
Palbociclib
The serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.
Panobinostat
The serum concentration of Fesoterodine can be increased when it is combined with Panobinostat.
Paregoric
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.
Paroxetine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.
Pazopanib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pazopanib.
Peginterferon Alfa-2b
The serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pentamidine.
Pentazocine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.
Pentobarbital
The metabolism of Fesoterodine can be increased when combined with Pentobarbital.
Pergolide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pergolide.
Perhexiline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perhexiline.
Perphenazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.
Phenobarbital
The metabolism of Fesoterodine can be increased when combined with Phenobarbital.
Phentermine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.
PHENTERMINE RESIN
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.
Phenylbutyrate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phenylbutyric acid.
Phenytoin
The metabolism of Fesoterodine can be increased when combined with Phenytoin.
Physostigmine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Physostigmine.
Pimozide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.
Pindolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.
Pioglitazone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pioglitazone.
Pipecuronium
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.
Pipothiazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.
Pirenzepine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.
Pirinitramide
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Piritramide.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Fesoterodine.
Posaconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Posaconazole.
Potassium Chloride
Fesoterodine may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Fesoterodine.
Pravastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.
Praziquantel
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.
Primaquine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Primaquine.
Primidone
The metabolism of Fesoterodine can be increased when combined with Primidone.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Fesoterodine.
Proguanil
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Proguanil.
Promazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promazine.
Promethazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.
Propafenone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.
Propiverine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Propiverine.
Propofol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.
Propoxyphene
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.
Propranolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.
Pyridostigmine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pyridostigmine.
Pyrilamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mepyramine.
Pyrimethamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine.
Quetiapine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.
Quetiapine fumarate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.
Quinidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.
Quinine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinine.
Rabeprazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.
Ranitidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.
Ranolazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranolazine.
Reboxetine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.
Remifentanil
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.
Rifabutin
The metabolism of Fesoterodine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Fesoterodine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Fesoterodine can be increased when combined with Rifapentine.
rimabotulinumtoxinB
Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.
Risperidone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.
Ritonavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.
Rivastigmine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rivastigmine.
Rolapitant
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rolapitant.
Ropinirole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.
Rosiglitazone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rosiglitazone.
Rotigotine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.
Rucaparib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rucaparib.
Rutin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rutin.
Saquinavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.
Saquinavir Mesylate
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.
Sarilumab
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.
Selegiline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.
Sertraline
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.
Sildenafil
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.
Siltuximab
The serum concentration of Fesoterodine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Fesoterodine can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin.
Solifenacin
The risk or severity of adverse effects can be increased when Solifenacin is combined with Fesoterodine.
Sorafenib
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.
ST. JOHN'S WORT EXTRACT
The serum concentration of Fesoterodine can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.
Sulconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulconazole.
Sulfanilamide
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide.
Sulfisoxazole
The metabolism of Fesoterodine can be decreased when combined with Sulfisoxazole.
Sulpiride
Fesoterodine may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine.
Tamoxifen
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tamoxifen.
Tapentadol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.
Tegaserod
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tegaserod.
Telaprevir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telaprevir.
Telithromycin
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telithromycin.
Temsirolimus
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.
Terbinafine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terbinafine.
Terfenadine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terfenadine.
Tetrahydrocannabinol
Fesoterodine may increase the tachycardic activities of Dronabinol.
Thioridazine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.
Thiothixene
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.
Ticagrelor
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticagrelor.
Ticlopidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticlopidine.
Timolol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Timolol.
Timolol Anhydrous
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Timolol.
Tioconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tioconazole.
Tiotropium
Fesoterodine may increase the anticholinergic activities of Tiotropium.
Tipranavir
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.
Tocilizumab
The serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Fesoterodine.
Topiramate
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.
Tramadol
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.
Tranylcypromine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.
Trimethaphan
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine.
Tripelennamine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tripelennamine.
Triprolidine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.
Trospium
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Trospium.
Tubocurarine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.
Tyrothricin
The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tyrothricin.
Umeclidinium
Fesoterodine may increase the anticholinergic activities of Umeclidinium.
Vecuronium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.
Vemurafenib
The serum concentration of Fesoterodine can be increased when it is combined with Vemurafenib.
Venlafaxine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine.
Verapamil
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.
Vilazodone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vilazodone.
Vinblastine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinblastine.
Vinorelbine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.
Voriconazole
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.
Yohimbine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Yohimbine.
Zafirlukast
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Zafirlukast.
Ziprasidone
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.
